{"id":"doi:10.1111/obr.12839","kind":"review","title":"Semaglutide as a promising antiobesity drug","authors":["Georgios A. Christou","Niki Katsiki","John Edward Blundell","Gema Frühbeck","Dimitrios Nikiforos Kiortsis"],"author_count":5,"year":2019,"published":"2019-02-15","venue":"Obesity Reviews","cited_by":159,"doi":"10.1111/obr.12839","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1111/obr.12839","archive_url":"https://space-kitty.com/papers/doi:10.1111/obr.12839","updated":null,"pmid":"30768766","pmcid":null,"openalex_id":"W2914029654","pdf_url":null,"abstract":null,"abstract_license":null,"license":null,"is_open_access":false,"retracted":false,"peer_reviewed":null,"categories":["Pharmacology and Obesity Treatment"],"details":null,"provenance":"openalex","attribution":"Metadata and citation counts: OpenAlex (CC0).","topics":[{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[]}